Gale R P, Feig S, Ho W G, Falk P, Winston D, Young L S, Opelz G, Opelz G, Tesler A, Sparkes R, Graze P R, Sarna G, Golde D W, Territo M C, Bryson Y, Gossett T, Naiem F, Fawzy F, Haskell C, Fahey J L, Cline M J
Lancet. 1977 Dec 10;2(8050):1197-200.
Survival in 33 patients with resistant leukaemia treated by marrow transplantation was compared with that of 37 matched patients treated by conventional and experimental chemotherapy. All patients in the transplant group were rendered free of detectable leukaemia for periods of from 36 days to more than 2 1/2 years, while only 6 patients in the chemotherapy group achieved a haematological remission. Overall survival in both groups was poor; however, 5 patients (15%) in the transplant group remain alive and in haematological remission 1--2 1/2 years after transplantation, while no patient in the chemotherapy group survived longer than 13 months. Bone-marrow transplantation appears to offer a small but distinct possibility of long-term survival in patients with acute leukaemia resistant to conventional therapy.
对33例接受骨髓移植治疗的耐药白血病患者的生存率与37例接受传统和实验性化疗的匹配患者的生存率进行了比较。移植组的所有患者在36天至超过两年半的时间内白血病检测呈阴性，而化疗组只有6例患者实现了血液学缓解。两组的总体生存率都很低；然而，移植组有5例患者（15%）在移植后1至两年半仍存活且处于血液学缓解状态，而化疗组没有患者存活超过13个月。对于对传统治疗耐药的急性白血病患者，骨髓移植似乎提供了一个虽小但明显的长期生存可能性。
